Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NCT02414204 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT02414204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02414204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Lead sponsor
University of Alabama at Birmingham
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2015
Completion date
June 30, 2018
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

improve endothelial function and decrease vascular stenosis